• Lilly's Covid-19 antibody reduced viral load faster than placebo, interim Phase II data show

    12 days ago - By MedCity News

    The company said that patients receiving LY-CoV555 at the 2,800mg dose showed a lower rate of hospitalization and emergency room visits than those on placebo. However, the other dose levels of the drug did not reach the viral load primary endpoint. An analyst called the data “mixed but constructive.”
    Read more ...